Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Back to alerts
ASTRAZENBSEASTRAZENECA PHARMA IND LT· Pharmaceuticals & BiotechnologyHighNeutral
Announced Mon, 10 Aug, 2026 · 13:52 IST

AstraZeneca India Q1 FY27: revenue up 30%, PAT down 32%

Revenue Growth 20pctExceptional ItemContingent Liabilities IncreasedResults View source PDFExplain this filing

ASTRAZEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-1.2%Reaction day
₹8200.00
prior close
₹8201.00
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-1.2% vs market
Pharmaceuticals peers, median of 165sector-0.1%-1.2% vs sector

On the reaction day the stock moved 1.2 pts less than Nifty Microcap 250 and 1.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-2.5
10m
-0.8
15m
-0.9
30m
-0.9
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-1.2-0.1-1.2-0.1-1.2
Next day
-3.2-0.2-2.9+0.0-3.2
2d
-3.7+0.1-3.9-0.0-3.7
3d
-5.1+0.3-5.4+0.3-5.4
4d
-5.7+0.4-6.1-0.5-5.2
5d
-6.7+0.5-7.2-1.1-5.6
1w
-8.5+0.3-8.8-1.8-6.7
15d
-15.3+1.9-17.1+0.2-15.5
1m
-16.5+2.2-18.7+1.7-18.3
2m
-27.8-1.2-26.6-1.8-26.0
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

AstraZeneca Pharma India Q1 FY27: revenue up 30% to Rs 6,828 Mn, driven by Oncology (+26%), Biopharmaceuticals (+36%) and Rare Disease. PAT fell 32% to Rs 379 Mn on higher expenses. Board appointed Arun Krishna as Additional Director. CFO Bhavana Agrawal moves to Non-Executive Director role. NPPA ordered Rs 165.8 Mn deposit as contingent liability for alleged drug overcharging.

Likely market impact

Strong revenue growth but profit fell sharply due to higher costs. New NPPA contingent liability of Rs 165.8 Mn may weigh on sentiment.